Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.842
Abstract: Two studies evaluated the effects of renal and hepatic impairment on pharmacokinetics and safety of rivipansel (NCT02813798, NCT02871570). A single intravenous 840‐mg rivipansel dose was administered to subjects with renal impairment or normal renal function… read more here.
Keywords: rivipansel; renal hepatic; hepatic impairment; impairment pharmacokinetics ... See more keywords
Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134803
Abstract: Methods: The RESET trial (NCT02187003) was a phase 3, randomized, double-blind, controlled study of rivipansel for VOC requiring hospitalization. Three hundred forty-five patients (204 adults and 141 subjects 6-17 years old) were randomized to an… read more here.
Keywords: discontinuation opioids; trial; early initiation; initiation treatment ... See more keywords
A Randomized Clinical Trial of the Efficacy and Safety of Rivipansel for Sickle Cell Vaso-occlusive Crisis (VOC).
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022015797
Abstract: The efficacy and safety of rivipansel, a predominately E-selectin antagonist, was studied in a phase 3, randomized, controlled trial for VOC requiring hospitalization (RESET). Three hundred forty-five subjects (204 adults and 141 children) were randomized… read more here.
Keywords: trial; voc; safety rivipansel; efficacy safety ... See more keywords